Patient demographics
| Characteristic | Overall (n=90) | Time since last CI dose | ||
| <24 months (n=37) | 24 to <36 months (n=27) | 36+ months (n=26) | ||
| Median age at time of survey (years; Q1, Q3) | 65 (54 to 74) | 65 (54 to 75) | 63 (54 to 70) | 66 (54 to 74) |
| Sex, n (%) | ||||
| Male | 51 (57) | 19 (51) | 16 (59) | 16 (62) |
| Female | 39 (43) | 18 (49) | 11 (41) | 10 (39) |
| Race, n (%) | ||||
| White | 84 (93) | 36 (97) | 22 (82) | 26 (100) |
| Asian | 1 (1) | 1 (3) | 0 (0) | 0 (0) |
| Unknown | 5 (6) | 0 (0) | 5 (19) | 0 (0) |
| Primary language, n (%) | ||||
| English | 88 (98) | 37 (100) | 25 (93) | 26 (100) |
| Other | 1 (1) | 0 (0) | 1 (4) | 0 (0) |
| Unknown | 1 (1) | 0 (0) | 1 (4) | 0 (0) |
| Median length of CI treatment (months; IQR) | 8 (2–24) | 11 (5–26) | 5 (3–17) | 5 (2–26) |
| Radiation prior to starting CI, n (%) | 15 (17) | 7 (19) | 3 (11) | 5 (19) |
| Radiation after starting CI, n (%) | 13 (14) | 5 (14) | 2 (7) | 6 (23) |
| Systemic anti-neoplastic therapy before CI, n (%) | 20 (22) | 2 (5) | 6 (22) | 12 (13) |
| ECOG at first CI dose, n (%) | ||||
| 0 | 86 (96) | 37 (100) | 27 (100) | 22 (85) |
| 1 | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 2 | 2 (2) | 0 (0) | 0 (0) | 2 (8) |
| 3 | 2 (2) | 0 (0) | 0 (0) | 2 (8) |
| Charlson Comorbidity Index | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Drugs received, n (%)* | ||||
| Ipilimumab | 29 (32) | 8 (22) | 5 (19) | 16 (62) |
| Nivolumab | 5 (6) | 4 (11) | 0 (0) | 1 (4) |
| Ipilimumab+nivolumab | 48 (53) | 18 (49) | 21 (78) | 9 (35) |
| Pembrolizumab | 37 (41) | 25 (68) | 9 (33) | 3 (12) |
| Durvalumab | 2 (2) | 0 (0) | 2 (7) | 0 (0) |
| Time since CI initiation, median months (IQR) | 40 (31–58) | 32 (20–37) | 36 (32–53) | 66 (52–104) |
*Individual patients may have received more than one drug, or a drug more than once in different regimens, therefore, totals exceed the total number of patients.
CI, checkpoint inhibitor.